一款临床前国产新药超8亿美元出海, 有何潜力?

医药时间
Nov 03, 2025

11 月 3 日,药捷安康宣布与 Neurocrine Biosciences 签署一项专利转让及研究合作协议。Neurocrine 公司获得药捷安康NLRP3 抑制剂在大中华区以外的开发、制造及商业化独家权利,药捷安康保留该药在大中华区的独家权利。该协议的总潜在价值为 8.815 亿美元。合作内容还涵盖关于发展 NLRP3 相关技术的研究合作。截图来源:药捷安康公告药捷安康专注于发现和开发肿瘤、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10